

SEQUENCE LISTING

<110> AMOUYEL, Philippe et al.

<120> Method for determining the susceptibility of a NIDDM patient toward sulfonylurea therapy

<130> P07337US00/BAS

<140>

<141>

<160> 3

<170> PatentIn Ver. 2.1

<210> 1

<211> 253

<212> DNA

<213> Homo sapiens

<220>

<221> exon

<222> (194)..(226)

<223> exon 17

<220>

<221> variation

<222> (191)

<223> corresponds to the intronic -3T/C change the present application refers to

<300>

<400> 1

atccaggtgc tgtgggaggg acagagattg agaagagtgc tttctgaccc cacagaggcc 60

atttggaac cctgggaatt ggtgggaggg ttggaggttc cggattgctt ctcccctaag 120

actcagcgtg atggaaaggc aatgggggtg gaactaactg gtgttggtct gttcccattt 180

gtgttcccag cag cct tcc tga cag cga gat agg aga gga ccc cag 226

gtacagcctt gggactgggg tcagaag 253

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:upstream primer

<400> 2

cccggcccca ctcacatctg

20

<210> 3
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: downstream
primer

<400> 3
ggaggatggt taaaaggaga tt

